These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 16098364)

  • 21. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate cancer volume at biopsy predicts clinically significant upgrading.
    Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
    J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
    J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
    J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Saturation biopsy improves preoperative Gleason scoring of prostate cancer.
    Kahl P; Wolf S; Adam A; Heukamp LC; Ellinger J; Vorreuther R; Solleder G; Buettner R
    Pathol Res Pract; 2009; 205(4):259-64. PubMed ID: 19106019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additional sampling of dorsal apex on systematic prostate biopsy: impact on early detection of prostate cancer.
    Miyake H; Harada K; Inoue TA; Takenaka A; Hara I; Fujisawa M
    Urology; 2007 Apr; 69(4):738-42. PubMed ID: 17445661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
    J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.
    Ochiai A; Trpkov K; Yilmaz A; Donnelly B; Babaian RJ
    J Urol; 2007 Mar; 177(3):907-10. PubMed ID: 17296373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE.
    Greene KL; Elkin EP; Karapetian A; Duchane J; Carroll PR; Kane CJ;
    J Urol; 2006 Jan; 175(1):125-9; discussion 129. PubMed ID: 16406887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
    Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
    Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological behavior of single focus prostate adenocarcinoma.
    Rice KR; Furusato B; Chen Y; McLeod DG; Sesterhenn IA; Brassell SA
    J Urol; 2009 Dec; 182(6):2689-94. PubMed ID: 19836800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
    Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
    Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer.
    Brassell SA; Kao TC; Sun L; Moul JW
    Urology; 2005 Dec; 66(6):1229-33. PubMed ID: 16360448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy.
    Patel DA; Presti JC; McNeal JE; Gill H; Brooks JD; King CR
    J Clin Oncol; 2005 Sep; 23(25):6157-62. PubMed ID: 16135482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
    Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
    Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
    Park HK; Hong SK; Byun SS; Lee SE
    Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade.
    King CR; McNeal JE; Gill H; Brooks JD; Srinivas S; Presti JC
    Urology; 2006 Jun; 67(6):1229-34. PubMed ID: 16765184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
    Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
    J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.